Investigating antioxidant therapy for steroid-resistant asthma

James Pinkerton (New Lambton Heights, Australia), James Pinkerton, Richard Kim, Ama-Tawiah Essilfie, Brittany Rae, Jemma Mayall, Md. Khadem Ali, Malcolm Starkey, Lisa Wood, Shyam Biswal, Jay Horvat, Philip Hansbro

Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding
Session: Asthma: mechanisms and biomarkers that promote clinical understanding
Session type: Poster Discussion
Number: 570
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
James Pinkerton (New Lambton Heights, Australia), James Pinkerton, Richard Kim, Ama-Tawiah Essilfie, Brittany Rae, Jemma Mayall, Md. Khadem Ali, Malcolm Starkey, Lisa Wood, Shyam Biswal, Jay Horvat, Philip Hansbro. Investigating antioxidant therapy for steroid-resistant asthma. Eur Respir J 2016; 48: Suppl. 60, 570

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Study of antioxidant use in patients with asthma exacerbations
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013

Evaluation of methotrexate in the treatment of severe asthma
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015


Clinical effectiveness of anti-IgE therapy in allergic severe asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Characterisation of a steroid-insensitive severe asthma model
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014

Experience with omalizumab in patients with moderate and severe asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for the pathogenesis of allergic airways disease
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016

Achievement of asthma control in patients with cold airway hyperresponsiveness at different variants of basic therapy
Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment?
Year: 2013


Combination therapy of ICSs/LABAs plus montelucastin patients with severe asthma
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015

Use of β-blockers and the risk of asthma exacerbations
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016


Small airways targeting of inhaled steroids for severe therapy resistant asthma in children
Source: International Congress 2015 – Paediatric asthma and allergy: asthma management
Year: 2015

When needed use of inhaled steroids in children with asthma
Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management
Year: 2014

Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015


Antioxidant efficiency in the treatment of asthma exacerbations
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015

P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016

Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment?
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013


Adherence to the treatment of patients with bronchial asthma
Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage?
Year: 2015


Evaluating omalizumab persistency of response after long-term therapy (XPORT)
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014


Acute exacerbations of asthma in Barcelona, the recent experience
Source: Annual Congress 2013 –Epidemiology of asthma
Year: 2013


Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016


Total and free IgE in evolution of severe asthma after omalizumab treatment
Source: International Congress 2016 – Asthma management
Year: 2016